Top Markets
#1 TENDIES TENDIES +31.34%
#2 ICON ICON +26.61%
#3 Cash Cat Cash Cat +22.92%
#4 Threshold Network Threshold Network +20.14%
#5 OSK OSK +15.74%
#6 Magma Finance Magma Finance +12.58%
#7 Asteroid Shiba Asteroid Shiba +12.44%
#8 Ape and Pepe Ape and Pepe +11.65%
#9 Kite Kite +11.54%
#10 龙虾 (Lobster) 龙虾 (Lobster) +10.56%
Coin of the day
TENDIES TENDIES
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.

AIM Vaccine Co., Ltd.

6660
Classement en actions #16560
Operating within the People's Republic of China, AIM Vaccine Co., Ltd.... Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Prix de l'action
$0.23090685
Capitalisation boursière
$282.73M
Changement (1 jour)
5.25%
Changement (1 an)
-64.30%
Pays
CN
Échange AIM Vaccine Co., Ltd. (6660)

Catégorie

Healthcare
Ratio P/B pour AIM Vaccine Co., Ltd. (6660)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de AIM Vaccine Co., Ltd., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour AIM Vaccine Co., Ltd. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.828 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.5116 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.2199 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9942 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH